A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist

Dose fractionation of CAR-T cells. A systematic review of clinical outcomes

(2023) Matthew Frigault et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

(2022) Marc Wehrli et al.   Journal for ImmunoTherapy of Cancer

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

(2022) Kai Rejeski et al.   Journal for ImmunoTherapy of Cancer

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities

(2022) Caroline Diorio et al.   Blood Advances

Long-Term Neurological Safety in B-Cell Lymphoma Patients Treated With Anti-CD19 CAR T-Cell Therapy

(2022) Renata Ursu et al.   NEUROLOGY

The use of ICU resources in CAR-T cell recipients: a hospital-wide study

(2022) Sandrine Valade et al.   Annals of Intensive Care

Interferon-γ blockade in CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

(2022) Michael Rainone et al.   Blood Advances

Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy

(2022) Sammita Satyanarayan et al.   Neurohospitalist

Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

(2022) Seema Patel et al.   BLOOD

The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

(2022) Kai Rejeski et al.   BLOOD

The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma

(2022) Kai Rejeski et al.   BLOOD

Dose–response correlation for CAR-T cells: a systematic review of clinical studies

(2022) Anand Rotte et al.   Journal for ImmunoTherapy of Cancer

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

(2021) John H. Baird et al.   Blood Advances

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

(2021) Élie Azoulay et al.   Lancet Haematology

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma

(2021) Kai Rejeski et al.   BLOOD

Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells

(2021) Daniel A Lichtenstein et al.   BLOOD

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

(2021) Olalekan O. Oluwole et al.   BRITISH JOURNAL OF HAEMATOLOGY

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity

(2021) Cristina Gutierrez et al.   CRITICAL CARE MEDICINE

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

(2021) Jae H Park et al.   BLOOD

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

(2021) Max S. Topp et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

(2021) Bianca D. Santomasso et al.   JOURNAL OF CLINICAL ONCOLOGY

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy

(2021) Di Wang et al.   Blood Cancer Journal

Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions

(2021) Jeanette Wat et al.   Journal of Allergy and Clinical Immunology-In Practice

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

(2021) Ying Wang et al.   Blood Advances

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma

(2021) Vanessa E. Kennedy et al.   Blood Advances

Intrathecal Chemotherapy: An Alternative Treatment Strategy to Prolonged Corticosteroids for Severe CAR T Associated Neurotoxicity

(2020) Filiz Yucebay et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)

(2020) Robert David Sandler et al.   Frontiers in Immunology

Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity

(2020) Andrea Schmidts et al.   Annual Review of Medicine

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma

(2020) Eugenio Galli et al.   BONE MARROW TRANSPLANTATION

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

(2020) Kitsada Wudhikarn et al.   Blood Cancer Journal

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

(2020) Kitsada Wudhikarn et al.   Blood Advances

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

(2020) Paolo Strati et al.   Blood Advances

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

(2020) Tania Jain et al.   Blood Advances

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis

(2020) Avirup Guha et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

(2020) Jing Pan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

(2020) Marcela V Maus et al.   Journal for ImmunoTherapy of Cancer

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions

(2019) Bradley D Hunter et al.   JNCI-Journal of the National Cancer Institute

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells

(2019) Philipp Karschnia et al.   BLOOD

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy

(2019) Joshua A. Hill et al.   BLOOD REVIEWS

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis

(2019) Jingshi Wang et al.   HAEMATOLOGICA

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

(2018) Kris M. Mahadeo et al.   Nature Reviews Clinical Oncology

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

(2018) Juliane Gust et al.   CNS DRUGS

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

(2009) M. Griffioen et al.   HAEMATOLOGICA